文献速递心境障碍儿童青少年精神

氟西汀联合认知行为治疗青少年抑郁症的随机对照试验

The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
PubMed 文献 · Lancet Psychiatry · 2019-07-29

YoDA-C试验纳入15-25岁中重度抑郁症患者153例,随机接受12周CBT联合氟西汀或安慰剂。未发现氟西汀联合CBT优于CBT联合安慰剂的证据。

要点

  • CBT联合氟西汀与联合安慰剂在12周MADRS评分变化上无显著差异。
  • 两组抑郁症状均较基线明显改善,但加用氟西汀未进一步降低症状。
  • 探索性分析提示合并焦虑症状或年龄较大者加药可能有益。

核心结论

  • 未发现证据表明在CBT基础上加用氟西汀比安慰剂更能减轻中重度青少年抑郁症的抑郁症状。

研究设计与样本

  • YoDA-C为随机、双盲、安慰剂对照、多中心临床试验,纳入15-25岁中重度MDD患者153例,随机1:1接受12周CBT联合氟西汀或安慰剂。

关键数值与推荐

  • 焦虑障碍共病比例:CBT联合安慰剂组47例(61%),CBT联合氟西汀组49例(64%)。
  • 过去一个月自杀意念比例:CBT联合安慰剂组55例(71%),CBT联合氟西汀组59例(78%)。
  • 第12周随访完成率:CBT联合安慰剂组59例(77%),CBT联合氟西汀组64例(84%)。

临床怎么用

  • 对于中重度青少年抑郁症,CBT联合氟西汀作为一线治疗未显示优于CBT联合安慰剂的额外获益。
  • 临床决策时可考虑患者是否合并焦虑症状或年龄较大,探索性分析提示这些亚组加药可能有益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear. We aimed to examine whether combined treatment with CBT and fluoxetine was more effective than CBT and placebo in youth with moderate-to-severe major depressive disorder. METHODS: The Youth Depression Alleviation-Combined Treatment (YoDA-C) trial was a randomised, double-blind, placebo-controlled, multicentre clinical trial. Participants were aged 15-25 years with moderate-to-severe MDD and had sought care at one of four clinical centres in metropolitan Melbourne, Australia. Patients were randomly assigned (1:1) to receive CBT for 12 weeks, plus either fluoxetine or placebo. Participants began on one 20 mg capsule of fluoxetine or one placebo pill per day. All participants received CBT, delivered by therapists in weekly 50-minute sessions and attended interviews at baseline, and at weeks 4, 8, and 12, during which they completed assessments with research assistants. Participants saw a psychiatrist or psychiatry trainee to complete medical assessments at the same timepoints. The primary outcome was change in the interviewer-rated Montgomery-Åsberg Depression Rating Scale (MADRS) score at 12 weeks. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12612001281886). FINDINGS: 153 participants (mean age 19·6 years [SD 2·7]) were enrolled from Feb 20, 2013, to Dec 13, 2016. 77 (50%) patients were allocated to CBT and placebo and 76 (50%) to CBT and fluoxetine. Participants had severe depression at baseline (mean MADRS score 33·6 [SD 5·1] in the CBT and placebo group and 32·2 [5·6] in the CBT and fluoxetine group), with high proportions of participants with anxiety disorder comorbidity (47 [61%] in the CBT and placebo group and 49 [64%] in the CBT and fluoxetine group) and past-month suicidal ideation (55 [71%] in the CBT and placebo group and 59 [78%] in the CBT and fluoxetine group). 59 (77%) participants in the CBT and placebo group and 64 (84%) in the CBT and fluoxetine group completed follow-up at week 12. After 12 weeks of treatment both groups showed a reduction in MADRS scores (-13·7, 95% CI -16·0 to -11·4, in the CBT and placebo group and -15·1, -17·4 to -12·9, in the CBT and fluoxetine group). There was no significant between-group difference in MADRS scores (-1·4, -4·7 to 1·8; p=0·39). There were five suicide attempts in the CBT and placebo group and one suicide attempt in the CBT and fluoxetine group (odds ratio 0·2, 0·0-1·8; p=0·21), and no significant between-group differences for other suicidal behaviours. INTERPRETATION: We did not find evidence that the addition of fluoxetine (rather than placebo) to CBT further reduced depressive symptoms in young people with moderate-to-severe MDD. Exploratory analyses showed that the addition of medication might be helpful for patients with comorbid anxiety symptoms and for older youth. FUNDING: Australian National Health and Medical Research Council.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Davey CG, Chanen AM, Hetrick SE, et al. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. Lancet Psychiatry. 2019. PMID: 31371212. doi:10.1016/S2215-0366(19)30215-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。